US specialty pharma firm AcelRx Pharmaceuticals (Nasdaq: AVRX) has announced the monetization of the expected royalty stream from the sales of Zalviso (sufentanil sublingual tablet system) in the European Union by its commercial partner, German family-owned Grunenthal. AcelRx’ shares gained 5.8% to $4.20 in pre-market trading on the news.
Gross proceeds from the sale are $65 million from PDL BioPharma (Nasdaq: PDLI). Specifically, PDL will receive 75% of the European royalties under the Grunenthal license as well as 80% of the first four commercial milestones, subject to a capped amount. AcelRx will receive 25% of the royalties, 20% of the first four commercial milestones, 100% of the remaining commercial milestones and all development milestones, including a potential $15 million payment for the approval of the Zalviso marketing authorization in Europe.
Proposed use of the proceeds
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze